PDS Biotechnology Corp

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, founded in 2005. It is developing targeted cancer immunotherapies, with its lead candidate PDS0101 (Versamune HPV) in Phase II trials for head and neck, cervical, anal, vaginal, vulvar, and penile cancers. Preclinical candidates include PDS0102 for acute myeloid leukemia, prostate, and breast cancer, and PDS0103 for ovarian, breast, colorectal, and lung cancers. The company is also developing PDS01ADC, an investigational interleukin-12 fused antibody-drug conjugate, and has license and collaboration agreements with the National Institutes of Health, Merck Eprova AG, the U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH.